First-line induction therapy with Sarclisa delays myeloma progression
Adding Sarclisa (isatuximab) to standard induction therapy for…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
FDA adds Darzalex Faspro to combo therapy for newly diagnosed MM
The U.S. Food and Drug Administration (FDA) has approved…
Blood test may predict patients’ responses to CAR T-cell therapy
A blood test measuring numbers of lymphocytes, a type…
Blenrep combinations for myeloma now under review in EU
A committee of the European Medicines Agency (EMA) has…
MMRF invests $1M to advance DCT’s new CAR T-cell therapy
Through its Myeloma Investment Fund, the Multiple Myeloma…
Leukemia & Lymphoma Society to launch 32nd Scenic Shore Bike Tour
The Leukemia & Lymphoma Society (LLS) is once…
